Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)

被引：0

作者：

Furie, Richard ^{[1
]}

Merrill, J. T. ^{[2
]}

Werth, V. P. ^{[3
,4
]}

Khamashta, M. ^{[5
]}

Kalunian, K. ^{[6
]}

Brohawn, P. ^{[7
]}

Illei, G. ^{[7
]}

Drappa, J. ^{[7
]}

Wang, L. ^{[7
]}

Yoo, S. ^{[8
]}

机构：

[1] North Shore LIJ Hlth Syst, New York, NY USA

[2] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA

[3] Philadelphia VA Med Ctr, Philidelphia, PA USA

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] St Thomas Hosp, Rayne Inst, Graham Hughes Lupus Res Lab, London SE1 7EH, England

[6] UCSD, Sch Med, La Jolla, CA USA

[7] MedImmune, Gaithersburg, MD USA

[8] Regenx Bio, Rockville, MD USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3223

引用

页数：4

共 50 条

[1] ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Furie, R.
Merrill, J. T.
Werth, V. P.
Khamashta, M.
Kalunian, K.
Brohawn, P.
Illei, G.
Drappa, J.
Wang, L.
Yoo, S.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 168 - 168
[2] ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Furie, R.
Merrill, J.
Werth, V.
Khamashta, M.
Kalunian, K.
Brohawn, P.
Illei, G.
Drappa, J.
Wang, L.
Yoo, S.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S4 - S4
[3] Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Furie, Richard
Khamashta, Munther
Merrill, Joan T.
Werth, Victoria P.
Kalunian, Kenneth
Brohawn, Philip
Illei, Gabor G.
Drappa, Jorn
Wang, Liangwei
Yoo, Stephen
[J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69 (02) : 376 - 386
[4] Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
Riggs, Jeffrey M.
Hanna, Richard N.
Rajan, Bhargavi
Zerrouki, Kamelia
Karnell, Jodi L.
Sagar, Divya
Vainshtein, Inna
Farmer, Erika
Rosenthal, Kimberly
Morehouse, Chris
de los Reyes, Melissa
Schifferli, Kevin
Liang, Meina
Sanjuan, Miguel A.
Sims, Gary P.
Kolbeck, Roland
[J]. LUPUS SCIENCE & MEDICINE, 2018, 5 (01):
[5] ANIFROLUMAB, AN ANTI-INTERFERON-A RECEPTOR MONOCLONAL ANTIBODY IN SYSTEMIC LUPUS ERYTHEMATOSUS- A META ANALYSIS
Razzack, A. Abdul
Razzack, S. Abdul
Shenasan, P.
Shenasan, N.
Mishra, S.
Zarrar, R.
Sosa, J. Pablo
Caceres, M. Mercedes Ferreira
Garimella, R.
Andrews, K.
Mukhtar, S.
Agolli, A.
Agolli, O.
Hassan, S.
Rocha Castellanos, D. M.
Pothuru, S.
Reddy, K. Theja
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 600 - 600
[6] THE EFFECT OF GEOGRAPHY ON THE EFFICACY OF SIFALIMUMAB, AN ANTI-INTERFERON-ALPHA MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS
Khamashta, M.
Illei, G.
Drappa, J.
Wang, L.
Greth, W.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 951 - 952
[7] The Effect of Geography on the Efficacy of Sifalimumab, an Anti-Interferon-Alpha Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus
Khamashta, M.
Illei, G.
Drappa, J.
Wang, L.
Greth, W.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S40 - S41
[8] Anifrolumab Anti-interferon-α receptor 1(IFNAR1) monoclonal antibody Treatment of systemic lupus erythematosus
Haddley, K.
[J]. DRUGS OF THE FUTURE, 2018, 43 (07) : 471 - 481
[9] ANIFROLUMAB REDUCES DISEASE ACTIVITY IN MULTIPLE ORGAN DOMAINS IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Merrill, J.
Furie, R.
Werth, V.
Khamashta, M.
Drappa, J.
Wang, L.
Illei, G.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S4 - S4
[10] ANIFROLUMAB REDUCES DISEASE ACTIVITY IN MULTIPLE ORGAN DOMAINS IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Merrill, J. T.
Furie, R.
Werth, V. P.
Khamashta, M.
Drappa, J.
Wang, L.
Illei, G.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 293 - 293

← 1 2 3 4 5 →